Standard vs. Biofilm Susceptibility Testing in Cystic Fibrosis (CF)

NACompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

March 31, 2004

Study Completion Date

November 30, 2007

Conditions
Cystic FibrosisChronic Bronchitis
Interventions
DRUG

IV amikacin

5-7.5 mg/kg every 8 hrs or previous dose; start at previous recent stable dose then monitor serum levels and adjust dose, if needed, per standard clinical practice at the site

DRUG

PO azithromycin

250 mg once daily

DRUG

IV ceftazidime

50 mg/kg every 8 hours, up to 2 grams every 8 hours

DRUG

PO ciprofloxacin

500 mg every 12 hours if weight \<50 kg 750 mg every 12 hours if weight ≥50 kg

DRUG

IV meropenem

40 mg/kg every 8 hours, up to 2 grams every 8 hours

DRUG

IV piperacillin-tazobactam

100 mg/kg of piperacillin component every 6 hours, up to 3 grams every 6 hours; antibiotic combination formulated in a fixed ratio, thus dosing is described for first component only

DRUG

IV ticarcillin-clavulanate

100 mg/kg of ticarcillin component every 6 hours, up to 3 grams every 6 hours; antibiotic combination formulated in a fixed ratio, thus dosing is described for first component only

DRUG

IV tobramycin

2.5-3.3 mg/kg every 8 hrs or previous dose; start at previous recent stable dose then monitor serum levels and adjust dose, if needed, per standard clinical practice at the site

Trial Locations (8)

15213

University of Pittsburgh Medical Center, Pittsburgh

43205

Ohio State University, Columbus

52242

University of Iowa, Iowa City

63110

Washington University St. Louis, St Louis

77030

Baylor College of Medicine, Houston

98195

University of Washington Medical Center, Seattle

45267-0557

University of Cincinnati, Cincinnati

98105-0371

Children's Hospital and Regional Medical Center, Seattle

All Listed Sponsors
collaborator

Cystic Fibrosis Foundation

OTHER

lead

Seattle Children's Hospital

OTHER

NCT00153634 - Standard vs. Biofilm Susceptibility Testing in Cystic Fibrosis (CF) | Biotech Hunter | Biotech Hunter